Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer
Katrin Almstedt, Anne-Sophie Heimes, Franziska Kappenberg, Marco Johannes Battista, Hans‐Anton Lehr, Slavomir Krajnak, Antje Lebrecht, Mathias Gehrmann, Kathrin Stewen, Walburgis Brenner, W. Weikel, Jörg Rahnenführer, Jan G. Hengstler, Annette Hasenburg, Marcus Schmidt
Topics & Concepts
MedicineImmunohistochemistryInternal medicineBreast cancerTrastuzumabOncologyExact testProportional hazards modelGrading (engineering)GastroenterologyHER2/neuHuman Epidermal Growth Factor Receptor 2CohortCancerPathologyBiologyEcologyHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesAdvanced Breast Cancer Therapies